Interferon-α2b-Induced RARRES3 Upregulation Inhibits Hypertrophic Scar Fibroblasts' Proliferation and Migration Through Wnt/β-Catenin Pathway Suppression.

Hypertrophic scar (HS) is a severe skin fibrotic disorder with unclear pathogenesis. Interferon-α2b (IFN-α2b) exerts inhibitory effects on HS in vivo and in vitro; however, the exact mechanism remains unclear. In this study, we aimed to evaluate the inhibitory effects of IFN-α2b on hypertrophic scar fibroblasts' (HSFs) proliferation and migration, and to further investigate the associated molecular mechanism. Cell Counting Kit-8 and CyQUANT assays were used to assess HSFs' proliferation; wound healing and Transwell assays were used to assess HSFs' migration; real-time quantitative polymerase chain reaction and Western blotting were used to detect messenger RNA and protein levels, respectively, of related genes; bioinformatics analysis was performed to predict the downstream target of IFN-α2b. Our findings are as follows: (1) IFN-α2b inhibited HSFs' proliferation and migration in a dose-dependent manner. (2) IFN-α2b inhibited HSFs' proliferation and migration by suppressing the Wnt/β-catenin pathway. (3) Retinoic-acid receptor responder 3 (RARRES3) was predicted as a functional downstream molecule of IFN-α2b, which was low in HSFs. (4) IFN-α2b inhibited HSF phenotypes and the Wnt/β-catenin pathway by upregulating RARRES3 expression. (5) RARRES3 restrained HSFs' proliferation and migration by repressing the Wnt/β-catenin pathway. In conclusion, IFN-α2b-induced RARRES3 upregulation inhibited HSFs' proliferation and migration through Wnt/β-catenin pathway suppression.

[1]  Zhandong Li,et al.  Ellagic acid exerts anti-fibrotic effects on hypertrophic scar fibroblasts via inhibition of TGF-β1/Smad2/3 pathway , 2021, Applied Biological Chemistry.

[2]  T. Mohr,et al.  Computational approaches in cancer multidrug resistance research: Identification of potential biomarkers, drug targets and drug-target interactions. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[3]  Xuefeng Li,et al.  Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155. , 2019, Annals of hepatology.

[4]  Olga Tanaseichuk,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[5]  Lianbo Zhang,et al.  Identification of the potential targets for keloid and hypertrophic scar prevention , 2018, The Journal of dermatological treatment.

[6]  I. Ng,et al.  Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. , 2017, Journal of hepatology.

[7]  P. Dziewulski,et al.  Hypertrophic scarring: the greatest unmet challenge after burn injury , 2016, The Lancet.

[8]  T. Jacques,et al.  Human IFNAR2 deficiency: Lessons for antiviral immunity , 2015, Science Translational Medicine.

[9]  R. Eckert,et al.  Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells , 2014, Cell Death and Differentiation.

[10]  E. Tredget,et al.  Biology and principles of scar management and burn reconstruction. , 2014, The Surgical clinics of North America.

[11]  J. Werner,et al.  Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells. , 2014, Experimental cell research.

[12]  R. Eckert,et al.  TIG3 - AN IMPORTANT REGULATOR OF KERATINOCYTE PROLIFERATION AND SURVIVAL , 2014, The Journal of investigative dermatology.

[13]  H. Anders,et al.  The antiviral cytokines IFN-α and IFN-β modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. , 2013, The American journal of pathology.

[14]  S. Goodbourn,et al.  Abstracts of the European Congress of Immunology. September 5-8, 2012. Glasgow, Scotland, United Kingdom. , 2012, Immunology.

[15]  M. P. Ceballos,et al.  Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma? , 2011, Biochemical pharmacology.

[16]  R. Eckert,et al.  TIG3 Tumor Suppressor-Dependent Organelle Redistribution and Apoptosis in Skin Cancer Cells , 2011, PloS one.

[17]  Dennis B. Troup,et al.  NCBI GEO: archive for high-throughput functional genomic data , 2008, Nucleic Acids Res..

[18]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[19]  A. Ghahary,et al.  Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[20]  R. Eckert,et al.  Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Ghahary,et al.  Transforming growth factor-β in thermally injured patients with hypertrophic scars : Effects of interferon α-2b , 1998 .

[22]  M. Jeschke,et al.  Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions , 2018, Advanced drug delivery reviews.

[23]  Madoka Sato.  Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. , 2006, Acta dermato-venereologica.